Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Two State-of-the-Art MRI Machines--Cutting-Edge Diagnosis and Research at Hadassah

The 3 Tesla Trio MRI and the 1.5 Tesla MRI, two sophisticated diagnostic tools, enable Hadassah Medical Organization physicians to examine the functioning of the body in real time.

Hadassah's MRI machines work six days each week, around the clock. Last year, a total of 16,848 examinations were carried out on patients of all ages, in comparison to 15,662 in the previous year.

Hadassah is the world's leading center in introducing new cell therapies for Multiple Sclerosis (MS) through the use of stem cells. The MRIs are playing an important role in the Phase II stem cell therapy clinical trials under the direction of Prof. Dimitrios Karussis, head of Hadassah's Multiple Sclerosis Center. With these Phase II trials investigating the optimal way of administering stem cell treatments, the MRIs enable the physicians to follow the effectiveness of the therapies. Participants undergo three baseline MRI scans before the injection of the stem cells and six monthly MRIs following the injection. One additional MRI is also performed after 12 months.

Hadassah's functional MRI machines (fMRI) are also used to observe blood-flow in the brain. With these MRIs, physicians can examine the brain function of stroke patients, for example, and determine their response to commands, such as to move a hand or retrieve a particular word.

While previously these sort of examinations were performed only on patients who were awake, Hadassah is now progressing to examinations on comatose patients, with a study headed by neurologists Dr. Shahar Arzy, MD, PhD and Dr. Netta Levin, MD, PhD.

Now that it is known that the brain is constantly active, even in comatose patients with chronic conditions, Hadassah's researchers are using the functional MRI to map brain activity over time in these unconscious patients.

Compassionate, well-trained staff coupled with cutting-edge technology makes rehabilitative care at HMO world-class . Patients who suffer a stroke or traumatic brain injury, or have orthopedic or neuromuscular conditions, are among the primary beneficiaries of the multidisciplinary rehabilitation care at Mount Scopus.






View all of our Impact Areas

"We hope to take this knowledge one step further, by using fMRI in the Emergency Room in acute conditions," reports Prof. J. Moshe Gomori, head of MRI in Hadassah's Department of Medical Imaging. Explaining that Hadassah's team has developed special mathematical techniques for analyzing the data, he adds: "We are about to publish interesting results of a study we have carried out using this system on patients with transient amnesia and those with neurological defects."

Hadassah also is a world innovator in the field of hyperpolarized MRI research, which aims to identify genetic anomalies and chemical changes during disease processes even before the disease is clinically apparent, making extremely early diagnosis possible. While at present the research is at the basic scientific stage, the ultimate goal is to attain the potential to use these techniques for human patients.
See Hadassah's Center for Hyperpolarized MRI Molecular Imaging: a Pioneer in its Field

"We are proud to continue to provide our patients with the most sophisticated examinations available, while investing in innovative research," comments Prof. Gomori. "All our programs truly are translational research, aimed at transferring knowledge from the patients' bedside to the laboratory, through our MRI Unit, and back to improve patient care."

Date: 12/12/2013

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America